Madison Scientific

Coming – June 25

Smarter Neurotech For 11.5 Million Patients

Date and Time

June 25

–

4:00 PM ET / 1:00 PM PT

Details will be provided upon RSVP approval

About this Event

You may have seen recent stories about Billy Joel’s diagnosis of Hydrocephalus, a neurological condition that affects 11.5 million patients globally. Caused by the buildup of cerebrospinal fluid in the brain, if untreated it can lead to cognitive decline, mobility issues, and death. Fortunately, it is treatable. Unfortunately, the current standard of care has a high failure rate and is prone to over drainage due to pressure spikes.

MadSci is developing the world’s first SmartShunt, that uses an intercranial sensor to monitor pressure and control a valve to prevent over and under drainage of fluid. This has been called a “game changer” by neurosurgeons and offers a myriad of benefits including:
  • Better outcomes, lower costs: Designed to reduce shunt failure, complications, false alarms, and unnecessary interventions through continuous monitoring
  • Compelling economics: High-margin implant with recurring software/data revenue potential

Join our fireside chat with MadSci CEO, Tyler Wanke, to hear how their SmartShunt fits within the current workflow and is poised to transform a market with >$100B long-term potential.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.